Breaking The CLD Bottleneck: Generate Stable High-Producing Clones In 14 Weeks

Cell line development is increasingly strained by longer timelines, inconsistent productivity, and the growing complexity of modern monoclonal antibody formats, including bispecifics and fusion proteins. A transposon-based CHO-K1 platform offers a streamlined path forward, enabling the rapid generation of stable, high-producing cell lines in under 14 weeks. High-titer pools consistently reach up to 5 g/L, with selected clones exceeding 7 g/L and maintaining performance and product quality over extended generations. Reduce development bottlenecks while improving reliability from early selection through bench-scale production.

Watch to see how this approach can reshape your CLD strategy without sacrificing stability or yield.